drugset / Trial / NCT05909527
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, non blind, randomized, single center study aimed at evaluating the safety, pharmacokinetic characteristics, and preliminary efficacy of CD7 CAR-T cell injection in r/r T-ALL/LBL subjects.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7 CAR-T | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | CD7 CAR-T | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD7 CAR-T | Cell therapy | 2e+06 cells/kg | Intravenous |